secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001171843-26-000922
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DOJ closes inquiry into Cassava Sciences; ends all government investigations
----------------------------------------------------------------------------

- DOJ Fraud Section closed previously-disclosed inquiry into research misconduct allegations.
- The related indictment in United States v. Wang was dismissed with prejudice on Oct 23, 2025.
- Company previously settled SEC negligence charges in Sept 2024 with monetary penalty.
- CEO Richard Barry says company remains focused on developing treatment for TSC-related epilepsy.
- No further government investigations pending against Cassava Sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/0001171843-26-000922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184326000922/f8k_021926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer